Drug Discovery

#Clinical trials #Database #Drug development #Research

Clinical trials database will save researchers time and resources

The National Institute for Health Research’s Innovation Observatory (NIHRIO), based at Newcastle University, has launched a comprehensive database of clinical trials as well as FDA-approved medical devices, diagnostics and digital applications. Designed as a free resource, researchers can access information about what research is in progress in their area… Read More

#News

#Cell / tissue culture #Drug development #Synthetic biology

Synthetic cells could help study drug activity in living tissues

Scientists have created new artificial tissues that mimic some of the complex characteristics and abilities of living tissues, paving the way towards unprecedented advances in medicine, soft-robotics, and micro-engineering. The University of Bristol-led breakthrough, published in Advanced Materials, has reported the first way to produce centimetre-sized artificial tissues of any… Read More

#News

#Antibodies #Cancer research #Drug development #Research

Flow Eighteen38 reagent antibodies licensed for cancer research

Flow Eighteen38, FairJourney Biologics (FJB) and the Hubrecht Institute are working together to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies for research tools for the group Hans Clevers. The Clevers group is studying molecular mechanisms of tissue development and cancer of various organs using organoids… Read More

#News

#Assay #Bioscience #Data #Drug discovery #Drug targets #Interview #Life sciences #Screening

Ask the expert: assisting researchers with hit-to-lead

Pelago Bioscience is a specialised CRO, focusing on its patented Cellular Thermal Shift Assay (CETSA), which can assess therapeutically relevant target engagement in cells or tissue of unmodified compounds against the native, full-length proteins of interest. Stina Lundgren, Principal Project Advisor, shared the company’s hit-to-lead expertise with Lu Rahman. CETSA… Read More

#Editor's Choice #Exclusive Content #News

#Biotherapeutics #Drug candidates #Drug development #Therapeutics

Eli Lilly and MiNA Therapeutics saRNA research collaboration

Eli Lilly and Company and MiNA Therapeutics have created a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. MiNA will utilise its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key… Read More

#News

#Cell and gene therapy #Drug delivery #Drug development #Drug innovation #Life sciences

RoslinCT selected as vaccines and advanced therapies training centre

RoslinCT has been confirmed as a National Training Centre, part of the Department for Business, Energy & Industrial Strategy (BEIS) sponsored Advanced Therapies Skills Training Network (ATSTN) initiative. The organisation is the second National Training Centre confirmed as part of the ATSTN initiative, which was set up to develop vaccine… Read More

#News

#Data #Drug development #Drug repurposing #Drug research

In vitro drug interaction data critical in drug repurposing

Listen to this article on the DDW Podcast: In the wake of Covid-19 interest in repurposing a drug for a different indication to the one it was developed for has been high. Madison Knapp, Marketing Communications Specialist, and Dr. Brian Ogilvie, Vice President of Scientific Consulting, SEKISUI XenoTech offer… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Clinical trial #Drug development #MS

‘Mega-trial’ for progressive multiple sclerosis (MS) to launch

Octopus, a world-first mega-trial for progressive multiple sclerosis (MS), will launch in the UK later in 2021, according to the MS Society. It is a clinical trial that is said will transform the way treatments for progressive MS are tested and could deliver new options up to three times faster. Read More

#News

#Biologics / Biotechnology #Cell sequencing #DNA #Drug development #Drug discovery #Genome editing #Genome sequencing #Life sciences #Sequencing #Synthetic biology

The new synthesis: How synthetic DNA technology is changing drug discovery

Listen to this article on the DDW Podcast: Dr Tim Brears, CEO, Evonetix and Dr Raquel Sanches-Kuiper, Director of Biology, Evonetix explore applications of synthetic DNA in drug discovery and development, the benefits and limitations of current methods, and the opportunities offered by emerging DNA synthesis technologies. On 16… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AstraZeneca #Biotherapeutics #Drug discovery #Immuno-oncology

Biotech collaboration to accelerate prostate cancer research

Alchemab has collaborated with AstraZeneca to work on a proof-of-concept study to build understanding of the fundamental biology of prostate cancer. Under the agreement, Alchemab’s novel drug discovery platform will be used as a diagnostic tool through the identification of disease biomarkers with potential to inform the development of novel… Read More

#News

#Biotechnology #Drug development #FDA #Research

The FDA expands lung-on-a-chip collaboration with CN Bio

The US. Food and Drug Administration (FDA) has extended its research collaboration with CN Bio for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using… Read More

#News

#Biotherapeutics #Cancer research #Drug development #Immuno-oncology #Pharmaceutical

Janssen seeks approval for refractory multiple myeloma drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Read More

#Cancer Research #News

#Data #Drug development #Drug discovery

China’s fast-track regulatory reforms not attracting non-Chinese companies

China has reformed its regulatory system in recent years to include various fast-track programs similar to the US, EU and Japan to incentivise the development of drugs for unmet medical needs and serious conditions. However, only a few companies based outside of China have been granted priority review status by… Read More

#News

#Antigen #Drug discovery #Immunology / Virology & Vaccines #Monoclonal antibodies

How to get your drug to market faster

The pressure to take your drug to market faster is increasing. To achieve a successful journey to the first clinical trial phase in the fastest time possible, Eppendorf has identified three key elements that it is addressing in an eBook.  Comply with audit requirements and relevant certifications  Drive process efficiencies… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Drug research #MS #Neuroscience #Stem cells

Mini 3-D brain models could speed up search for MS treatments

Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models – created using stem cells from human skin samples – will be… Read More

#News

#Bacteria #Drug discovery #Research

‘Last resort’ antibiotic pops bacteria like balloons

Scientists have revealed how an antibiotic of ‘last resort’ kills bacteria. The findings, from Imperial College London and the University of Texas, may also reveal a potential way to make the antibiotic more powerful. The antibiotic colistin has become a last resort treatment for infections caused by superbugs. However, despite… Read More

#News